Comparing the current results to its competitors, Janux Therapeutics Inc reported Revenue increase in the 2 quarter 2026 by 0 % year on year. The revenue growth was below Janux Therapeutics Inc 's competitors' average revenue growth of 17.27 %, achieved in the same quarter.
Janux Therapeutics Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 5.45 %
Janux Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in the pharmaceutical and biotechnology industries, focusing on the development of immuno-oncology and autoimmune disease treatments. It faces competition from large pharmaceutical and biotechnology firms with greater financial resources and expertise in research, development, manufacturing, clinical trials, regulatory approvals, and marketing. Industry consolidation through mergers and acquisitions may concentrate resources among fewer competitors. Smaller or early-stage companies also present competition, particularly through collaborations with larger firms. Competition extends to recruiting personnel, establishing clinical trial sites, enrolling subjects, and acquiring complementary technologies. Competitors identified include AbbVie, Amgen, AstraZeneca, Biogen, Bristol Myers Squibb, Gilead, GSK, Johnson & Johnson, Lilly, Merck & Co., Novartis, Pfizer, Regeneron, Roche/Genentech, Sanofi, and Takeda.
December 5, 2024
Janux Therapeutics, Inc. (Nasdaq: JANX), a pioneering clinical-stage biopharmaceutical company, has recently announced a substantial public offering valued at $350 million. The offering, aimed at accelerating its innovative pipeline of immunotherapies, comes at a pivotal time for the company, which is actively leveraging its proprietary technologies the Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms to address critical unmet medical needs in oncology.The specifics of the offering include 5,317,460 shares of common stock priced at $63.00 each, alongside pre-funded warrants that enhance the offering s attractiveness to investors. This financial maneuver is poised...
Zai Lab Limited operates as a biopharmaceutical company primarily in China. The company seeks to discover, develop, and commercialize innovative medicines to address unmet medical needs in the country. Zai Lab focuses on licensing and acquiring clinical stage or late-stage development drugs, and then progressing them through regulatory approval and commercial launch.
Actinium Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of targeted therapies for the treatment of various cancers.
TG Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing innovative treatments for patients with hematological malignancies and autoimmune diseases.
TherapeuticsMD Inc is a pharmaceutical company that focuses on developing and commercializing innovative hormone therapy products for women. Their business model revolves around research, development, and marketing of prescription and over-the-counter products catering to women's health needs. By leveraging strategic partnerships and collaborations, they aim to bring their products to market, ultimately improving the quality of life for women.
Sources:
Janux Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Janux Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
